China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT Genotype

Launched by SHENZHEN AUSA PHARMED CO.,LTD · Jul 13, 2021

Keywords

ClinConnect Summary

The China Stroke Primary Prevention Trial 2 is studying the best way to prevent strokes in people who have high blood pressure (hypertension) and a specific genetic marker called the MTHFR 677 TT genotype. The study involves 24,000 participants and will compare three different treatments. Participants will take either a standard blood pressure medication called amlodipine, a combination of amlodipine and folic acid, or a combination of amlodipine, folic acid, and another form of folate. The main goal of the trial is to see which treatment helps prevent the first occurrence of an ischemic stroke, which happens when blood flow to the brain is blocked.

To be eligible for this trial, participants need to be between 45 and 75 years old, diagnosed with high blood pressure, and have the MTHFR 677 TT genotype. They should not have a history of stroke or serious heart conditions. If you join the trial, you will be randomly assigned to one of the treatment groups and will take the medication once daily for a set period. It’s important that you can follow the study guidelines and want to participate. This trial aims to provide valuable information that could help improve stroke prevention strategies for people with similar health conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Men and women, aged ≥45 and \<75 years.
• • 2. Hypertension: Previously diagnosed with primary hypertension and has been taking antihypertensive medication within the past two weeks; OR has not been taking antihypertensive medications within the last two weeks, but meets the following criteria for hypertension: SBP≥140 mmHg and/or DBP≥90 mmHg (average of at least 2 measurements each time) at two separate (not on the same day) clinical visits.
• • 3. MTHFR 677 TT genotype (based on the test results from the central laboratory during the screening period or a previous official test report from a laboratory with medical testing qualifications).
• • 4. Voluntarily participates and has given signed informed consent.
• Randomized-treatment phase inclusion criteria:
• • 1. Good compliance during the run-in period, and unlikely to discontinue treatment;
• • 2. No stroke or cardiovascular events during the run-in period;
• • 3. The participant voluntarily agrees to continue the study.
• Exclusion Criteria:
• • 1. Previously diagnosed secondary hypertension;
• • 2. Previously diagnosed stroke;
• • 3. Previously diagnosed myocardial infarction;
• • 4. Previously diagnosed heart failure;
• • 5. Previously diagnosed atrial fibrillation;
• • 6. Cardio-cerebral-kidney revascularization and/or other large arterial stent;
• • 7. Currently on dialysis, or diagnosed with stage 4-5 chronic kidney disease, or eGFR \<30 mL/ min/1.73m²;
• • 8. Known to have congenital (such as aortic stenosis) or acquired organic heart disease;
• 9. Known to have any of the following severe diseases or conditions:
• • 1. Digestive system: i. Previously diagnosed with any form of viral hepatitis that is currently still in the active phase; ii. Abnormal liver function test before enrollment (any of ALT, AST, GGT, TBIL, DBIL test 3 times higher than normal, or ALB≤30g/L); iii. Subtotal gastrectomy and/or gastrojejunostomy;
• • 2. Respiratory system: previously diagnosed with pulmonary heart disease;
• • 3. Presence of malignant tumors or other severe diseases;
• • 4. Presence of long-term gastrointestinal symptoms such as ; anorexia, decreased appetite, nausea, and abdominal bloating;
• • 5. Previously diagnosed with vitamin B12 deficiency and/or its related diseases.
• • 10. Participant, at the investigator's discretion, is assessed to be unsuitable for the study, for reasons including but not limited to the presence of abnormal laboratory results, or clinical conditions;
• • 11. Prior history of significant intolerance due to adverse reactions resulting from usage of amlodipine or other CCBs, valsartan or other ARBs, indapamide or other similar diuretics, metoprolol tartaric acid or other beta-blockers, or any drugs or health products containing folate or folic acid;
• • 12. Regular consumption of folic acid or vitamin B compounds, or other compounds containing folic acid in the past 3 months;
• 13. The presence of any of the following conditions that could negatively influence a participant's ability to consent or participate in the trial:
• • 1. Dementia;
• • 2. Severe mental disorders;
• • 3. Inability to express informed consent;
• • 4. Unlikely to complete the study follow-up as specified by the protocol, or plans to relocate outside of the study area in the near future;
• • 5. History of poor compliance when taking antihypertensive medications or is expected to have poor compliance during the study;
• • 14. Refusal to participate, or inability to modify current drug regimen;
• • 15. Women who are pregnant or breastfeeding; or subjects of childbearing potential who are unwilling or unable to use effective contraception during the study period.
• • 16. Within one month prior to the first visit, having participated in any clinical trial for a drug that has not yet been officially approved by the state or is not currently approved for sale; or currently participating in any clinical trial that could potentially impact the results of this study (medication use, drug efficacy, drug interaction, etc.).